Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO bought $500,000 at $2.82 two months ago.
Do you hold some PSDV?
Why?
Congrats Surf, you were right again.
Nice call last week...
I'm holding ABIO from months, but expected a stronger move on today's news.
Do you mean the large short position will drive the price dramatically up?
Which stocks are you looking for an year end bounce?
They have few shares outstanding for a R/S, don't you think?
Do you think that ABIO will deserve us a big surprise to avoid delisting?
I don't see any Insiders buying...Do you mean that?
Ok, I see the stock capped at $1.00. Any reason?
Yes, big blocks of 200k shares are scooped up every day.
Shorts are betting on a R/S...
ANDS could be the next VRUS in the Hepatitis C market
http://www.xconomy.com/san-diego/2011/09/06/dramatic-changes-in-hepatitis-c-treatment-expected-to-continue/
http://www.cnbc.com/id/44449463
I tend to agree with you. By now I would be careful with the buying, due to the incertain direction of the market that is set for another correction in Septemper. The situation in Europe is critical, and I'm waiting for another leg down.
<<As of July 8, 2011, shares of common stock in an aggregate offering amount of $19,156,051 have been sold under the July 21, 2010, January 1, 2011, June 1, 2011, and June 29, 2011 prospectus supplements, and no further sales of shares will be made under such prospectus supplements>>.
Cash is improved.
<<Sales of common stock under the July 8, 2011 prospectus supplement will be made from time to time as market conditions warrant, in the Company's discretion.>>
"In the Company's discretion" means that now is not time for ATM sales. I'm accumulating step by step from $2 to wherever down it will go.
And I'm planning to sell in the $4...$6 area...
GLTA
Ok bought some today, maybe a partnership or a buyout?
I have also some put on silver and gold, waiting for a rest in Middle East (Libya).
Don't know why the dilution didn't take place at the time when OXGN was @$6.00. Could bounce back soon... Anyway I'm out, sold two weeks ago, too risky.
Seems to me that the shorts want to cover but they can't find shares. Thoughts?
Bought back some today on the weakness, waiting for the FACT data at ASCO.
GLTA
In eight weeks Heplisav will be the standard of care for patients with Hepatitis B. Not many shares are available to cover the short positions...
Sunesis is ready for a powerful bounce.
GLTA
Dilution? This is a ten bagger stock. Maybe at $10 you will see the dilution.
OXiGENE's novel Cathepsin L inhibitors demonstrate antitumor efficacy in preclinical studies (OXGN) 1.71 : Co announces the presentation of positive preclinical data supporting development of its novel, non-peptidic cathepsin L inhibitors as anticancer agents. The data were presented at the Meeting of the American Association of Cancer Research. In a presentation titled, Abrogation of Prostate Cancer Cell Metastatic Phenotype by Cathepsin L Inhibition, it was demonstrated that OXiGENE's lead cathepsin L inhibitor, KGP94, inhibited the metastatic phenotype in the three human prostate cancer cell lines. KGP94 mediated abrogation of tumor cell migration and invasion occurred in the absence of cytotoxic effects and was a consequence of an inhibitory effect on secreted and not nuclear cathespsin-L.
OXiGENE'S Novel Cathepsin L Inhibitors Demonstrate Antitumor Efficacy in Preclinical Studies.
SOUTH SAN FRANCISCO, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the presentation of positive preclinical data supporting development of its novel, non-peptidic cathepsin L inhibitors as anticancer agents. The data were presented today at the 102nd Annual Meeting of the American Association of Cancer Research in Orlando, Florida.
Cysteine cathepsins are a family of lysosomal proteases that are often up-regulated in a variety of cancers and that have been implicated in key processes in cancer progression. Small molecule inhibitors of the cysteine protease cathepsin L have the potential to limit degradation of extracellular matrix in the normal tissue surrounding the tumor, thus retarding cancer metastasis. It has also been established that cathepsin L is involved in blood vessel development, and thus inhibitors have the potential to suppress tumor growth and dissemination through an anti-angiogenic effect.
"The discovery of new chemotherapeutic strategies for inhibiting the growth and spread of cancer, such as our novel class of cathepsin inhibitors, represents an important achievement in the effort to enhance both cancer patient quality of life and survival. We are very encouraged by the preclinical safety and efficacy data presented at the AACR meeting with our small molecule cathepsin L inhibitors. Our goal is to advance these promising agents towards clinical evaluation," said Dr. Dai Chaplin, OXiGENE's Chief Scientific Officer
In a presentation titled, Abrogation of Prostate Cancer Cell Metastatic Phenotype by Cathepsin L Inhibition, Dhivya Sudhan and Professor Dietmar Siemann from The Shands Cancer Center at The University of Florida demonstrated that OXiGENE's lead cathepsin L inhibitor, KGP94, inhibited the metastatic phenotype in the three human prostate cancer cell lines. KGP94 mediated abrogation of tumor cell migration and invasion occurred in the absence of cytotoxic effects and was a consequence of an inhibitory effect on secreted and not nuclear cathespsin-L.
Professor Siemann commented: "Our findings strongly support a mechanism of action where KGP94 affects the ability of cathepsin-L to break down extracellular matrix, which is important in invasive and angiogenic processes."
A second presentation, titled Development and Initial Evaluation of the Antitumor Activity of a Functionalized Benzophenone Thiosemicarbazone Inhibitor of Cathepsin L, by Professors Mary Lynn Trawick and Kevin G. Pinney from Baylor University and Professor Michael Horsman from Arhus University Hospital in Denmark, demonstrated that KGP94 and other structurally related compounds inhibited the invasion and migration of DU145 prostate cancer cells through matrigel. In addition, the professors presented initial in vivo data from a mouse breast cancer model showing significant antitumor effects against both recently implanted and established tumors. These antitumor effects are consistent with a mechanism impacting tumor growth and vascularization.
Sold everything yesterday at $0.88. Biovail news was very disappointing. They are now a one trick pony and without BLS, cash is needed for PDP trial. R/S or dilution are a real threat.
JMP Securities Healthcare Conference should be a positive catalyst for this stock. Charged few thousands @$0.97 today, really don't know why ACAD is so cheap now. Small float, no diluition in sight, maybe the speculation is forcing the price down.
Picked up some last week and still holding. Don't know if it has leg...
With 69 MM market cap, its lead product candidate Amigal in Phase III development for the treatment of Fabry disease, this stock could be a ten bagger. Just hold until the end of Phase III.
I wonder how many buy orders in the $0.45 area, when tomorrow the stock will be delisted from Nasdaq...
86,700 shares for sale @$0.86 and nobody is buying...
Good news for leukemia patients. Bought some this evening, market cap and floating are small, the potential market in US is 200,000. I didn't follow the stock but it seems to me a good long term hold. How is the cash burn rate of the company? Will they issue new shares (I mean diluition), or have they enough cash to go alone? Some revenue?
Bought 10,000 @$1.37. Never sold or bought from May.
I've never sold nor bought during the spike. Looks like somebody start covering.
Seems that A.F. was wrong again:
http://www.thestreet.com/story/10575223/6/dendreon-vion-and-allos-biotech-mailbag.html
Well, now ABIO is soaring. Any news?
ABIO sank 80% in two months with a great drug in the pipeline.
Why nobody cares about the potential of Gencaro?
Is the same story of DNDN some year ago when the FDA denied the approval?